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ABSTRACT 
 
Cerebral hypoperfusion is an early feature of Alzheimer’s disease (AD) that influences the 
progression from mild cognitive impairment to dementia. Understanding the mechanism is of 
critical importance in the search for new effective therapies. We hypothesised that cerebral 
hypoperfusion promotes the accumulation of amyloid-β (A) and degenerative changes in the 
brain and is a potential mechanism contributing to development of dementia. To address this 
we studied the effects of chronic cerebral hypoperfusion induced by bilateral carotid artery 
stenosis on A peptide pools in a transgenic mouse model of AD (Tg-SwDI) at an age when 
fibrillar amyloid burden is minimal. Cerebrovascular integrity was characterised by 
quantifying the occurrence of microinfarcts and haemorrhages and compared to wild-type 
mice without A. A significant increase in soluble A peptides (Aβ40/42) was detected after 
1 month of hypoperfusion in the parenchyma in parallel with elevated amyloid precursor 
protein (APP) and APP proteolytic products. Following 3 months, a significant increase in 
insoluble Aβ40/42 was determined in the parenchyma and vasculature. Microinfarct load was 
significantly increased in the Tg-SwDI as compared to wild-type mice and further 
exacerbated by hypoperfusion at one and three months. In addition, the number of Tg-SwDI 
hypoperfused mice with haemorrhages was increased compared to hypoperfused wild-type 
mice.  Soluble parenchymal Aβ was associated with elevated NADPH Oxidase-2 (NOX2) 
which was exacerbated by one month hypoperfusion. We suggest that in response to 
hypoperfusion, increased Aβ production/deposition may contribute to degenerative processes 
by triggering oxidative stress promoting cerebrovascular disruption and the development of 
microinfarcts. 
 
 
 
 Clinical perspective: 
 Cerebral hypoperfusion influences the progression from mild cognitive impairment to 
dementia such as Alzheimer’s disease. 
 The mechanisms may involve promotion of amyloid production/deposition and 
degenerative changes (such as microinfarcts).  
 NADPH Oxidase-2 may present a key target to protect against hypoperfusion-induced 
changes. 
 
Introduction 
Vascular risk factors have a major influence on age-related neurodegeneration and dementia 
[1].  Furthermore, it is now recognised that vascular dysfunction and cerebral hypoperfusion 
are evident in the early stages of Alzheimer’s disease (AD) [2, 3]. The reduction in cerebral 
perfusion correlates with the severity of dementia and evidence from longitudinal 
epidemiological and neuroimaging studies suggest that underlying chronic cerebral 
hypoperfusion contributes to cognitive decline [3-5]. Regional alterations in brain perfusion 
may also predict those at risk of progression from mild cognitive impairment to dementia [4, 
5]. 
 
The mechanism by which chronic cerebral hypoperfusion may lead to cognitive impairment 
is being explored through animal models. Our work, and others, has shown that cerebral 
hypoperfusion leads to cognitive decline through mechanisms that initially involve hypoxia-
induced white matter injury, endothelial dysfunction, microvascular damage and a sustained 
pro-inflammatory response [6-11]. Prominent gliovascular damage and the development of 
vascular lesions (microinfarcts and haemorrhages) [10]
 
are found with sustained 
hypoperfusion after several months.  
 
Cerebral microinfarcts are a common finding in AD brains [12, 13] and linked to cerebral 
amyloid angiopathy (CAA) [14-18]. Additionally, microinfarction has been shown to occur 
regionally in areas of brain hypoperfusion in AD patients [19]
 
and, as indicated, in models of 
cerebral hypoperfusion [10, 20]. Importantly, cerebral microinfarcts have been implicated as 
important contributors to cognitive impairment [21-23]. Although the mechanisms leading to 
microinfarct formation remain unknown, oxidative stress and inflammation, as the result of 
cerebrovascular alterations, have been suggested as possible contributors [24, 25]. NADPH 
Oxidase-2 (NOX2) constitutes the main reactive oxygen species (ROS) source in the brain 
and it has a critical role in cell death following ischaemic insults [24-26]. Notably, mice 
lacking NOX2 develop significantly reduced infarct volumes following transient cerebral 
ischemia [26-28]. Moreover, NOX2 has been shown to be involved in post-ischaemic brain 
inflammation, which exacerbates the progression of brain injury [24].  
 
 
Increasing evidence demonstrates an association between Aβ-induced neuronal damage and 
oxidative stress, which has been shown to involve microglial activation [29-34]. Aβ is able to 
increase the processing of pro-interleukin-1β (IL-1β) into mature IL-1β in microglia via 
increased reactive oxygen species [35]. In addition, transgenic amyloid protein precursor 
mice (TgAPP) lacking NOX2 showed improved cerebrovascular function and behavioral 
performance through reduction of oxidative stress independently of Aβ accumulation [36] 
suggesting that the neurovascular alterations observed in this model are in part the result of 
oxidative stress induced by Aβ accumulation. Furthermore, cerebral hypoperfusion has been 
shown to lead to the accumulation of amyloid in the brain [20]. Together, this evidence 
suggested a possible mechanism by which chronic cerebral hypoperfusion may lead to 
progression of dementia by promoting  degenerative changes, such as microinfarcts,  and 
increased Aβ deposition through oxidative stress pathways. However the evidence linking 
these pathways was lacking.   
 
This study aimed to build on our previous work to investigate the long-term effects of mild 
cerebral hypoperfusion in TgAPP mice with the prediction that this would lead to alterations 
in Aβ pools causing vascular amyloid accumulation and degenerative changes, the latter of 
which would be more severe than in wild-type mice lacking Aβ.  The effects of mild chronic 
cerebral hypoperfusion on the dynamics of Aβ 40/42 pools were assessed in the parenchyma 
and vasculature of TgAPP mice. Since both hypoperfusion and Aβ have been linked to the 
presence of microinfarcts, the load of these and haemorrhagic lesions were measured. 
Furthermore, potential links between hypoperfusion, Aβ and NOX2 with the development of 
microinfarcts were investigated.  
 
 
Methods 
 
Animals 
Transgenic mice (Tg-SwDI) overexpressing the human APP, harbouring the Swedish 
K670N/M671L, Dutch E693Q and Iowa D694N mutations under the control of the Thy1 
promoter [37] on a C57Bl/6J background were purchased from Jackson Laboratories and 
subsequently bred in house and maintained on a homozygous background. Wild type mice 
(C57Bl/6J) were purchased from Charles River Laboratories. All procedures were authorized 
under the project licence number 60/4350 held by Prof. Horsburgh, approved by the UK 
Home Office and the University of Edinburgh's Ethical Review Committee and adhered to 
regulations specified in the Animals (Scientific Procedures) Act (1986). 
 
Chronic cerebral hypoperfusion 
Chronic cerebral hypoperfusion was induced as previously described in mice at 4-5months 
old [6-10]. Mice were anaesthetized with 1.5% isoflurane, and microcoils (0.18 mm internal 
diameter; Sawane Spring Co. Japan) were applied permanently to both common carotid 
arteries. Sham animals underwent identical surgical interventions without application of 
microcoils. The recovery of the mice was closely monitored with weight and general health 
recorded regularly. The surgeon was blind to the genotype of the mice and the final analysis 
were conducted blind to the surgical intervention and genotype. 
 
Tissue processing for histopathology 
At either 1 month (Tg-SwDI: n = 9 sham/10 hypoperfused; wild-type: n = 12 sham/11 
hypoperfused) or 3 months (Tg-SwDI: n = 9 sham/ 9 hypoperfused; wild-type: n = 10 
sham/10 hypoperfused) after surgery, mice were transcardially perfused with 20 ml of 
heparinized phosphate buffered saline (PBS) and then with 20 ml of 4% paraformaldehyde 
(PFA) in 0.1% phosphate buffer (pH 7.4). After perfusion brains were removed, cut along the 
midline and both hemibrains were post-fixed in 4% PFA for 24 hours. The left hemibrain was 
washed for 1 hour in phosphate buffer and 30 μm thick sagittal sections were produced with a 
vibratome (Hydrax V50, Zeiss). Sections were collected and stored in cryoprotective medium 
(30% glycerol/30% ethylene glycol/40% PB) at -20ºC until use. The right hemibrain was 
transferred to 70% ethanol followed by paraffin processing and sagittal sections (6 μm 
thickness) were cut for quantification of microinfarcts and haemorrhages. 
 
Immunohistochemistry 
Immunohistochemistry was carried out according to standard procedures. Vibratome 
sections, at anatomical level corresponding to 1.92 mm from midline were rinsed with PBS 
followed by tris-buffer (pH 7.6) and then mounted onto superfrost plus slides (VWR 
International). Sections were incubated through a series of alcohols (100%, 90% and 70% 
ethanol) and then equilibrated in PBS 0.1% triton. Antigen retrieval was performed by 
submerging slices in 10 mM citrate buffer (pH 6) at 100 °C under pressure for 10 minutes. 
Subsequently, retrieval using 10% proteinase K for 10 minutes at room temperature was 
performed. Samples were blocked with 20% normal serum 0.5% BSA and then incubated 
with the antibody solution (6E10 1:1000, Sigma 39320; anti-collagen IV 1:800, Fitzgerald 
70R-CR013x), overnight at 4 °C. Finally, antigens were visualized by incubating with the 
secondary antibody solution (anti-rabbit alexa fluor 546 1:500, Invitrogen A11010; anti-
mouse alexa fluor 488 1:500, Invitrogen A11001).  
 
Paraffinized tissue slices, at anatomical levels corresponding to 1.56 mm and 1.92 mm from 
midline were deparaffinized with heat (60 °C) followed by incubation in xylene. Samples 
were later incubated in 100% ethanol and then covered with 3% H2O2. Citrate retrieval was 
performed as described above. Subsequently, tissue sections were blocked with 10% serum 
0.5% BSA and then incubated with anti-Iba1 1:1000 (Menarini MP290) overnight at 4 °C. 
Slides were incubated with biotinylated anti-rabbit 1:100 (Vector BA1000) for 1 hour at 
room temperature followed by incubation with Vectastain Elite ABC reagent (Vector Labs). 
Antigens were visualized with diaminobenzidine solution (Vector Labs).  
 
Analysis of immunohistochemistry  
Immunolabelled vibratome sections were analysed using a laser scanning confocal 
microscope (Zeiss LSM 510, Germany). Images were selected from the thalamus since this is 
a brain region in TgSwDI mice that has most amyloid deposition with age. Four images of 
the thalamus per brain were acquired with a 40x objective at a 1024 x 1024 pixel resolution. 
Parenchymal Aβ load was determined by subtracting the percentage of vascular staining 
within a defined area from the percentage of Aβ staining in that area. Colocalization analysis 
for blood vessels and Aβ was done by calculating the Manders coefficient and data presented 
as % vascular amyloid. Images from immunolabelled paraffin sections were acquired at 4x 
magnification using a QImaging QICAM MicroPulisher 3.3 camera (QImaging, Surrey, BC, 
Canada) connected to a Olympus BX51 microscope (Olympus UK, Southendon-Sea, UK). 
Microglial burden was assessed by measuring the percentage of stained area occupied by 
Iba1 immunostaining. All measurements were carried out using Image J software (v1.42q). 
 
Histological detection of microinfarcts and haemorrhages  
Deparaffinized sections were stained with haematoxylin and eosin (H&E) and Perls Prussian 
blue using standard protocols to determine the presence of ischaemic tissue damage and 
haemorrhages respectively. Tissue sections at anatomical level corresponding to -1.70 and -
2.18 mm from Bregma were analysed and two sections per mouse. Four images of the 
thalamus were acquired at 10x magnification. Microinfarcts were defined as sharply 
delineated areas of tissue pallor on H&E sections that were accompanied by microglial 
proliferation identified by Iba1 immunostaining in adjacent sections. The area covered by 
infarcted tissue was measured using Image J software (v1.42q). Haemorrhages were 
identified by the presence of ferric iron deposits on Perls stained sections (Supplementary Fig. 
S1, b). The presence or absence of haemorrhages in each mouse was recorded.  
 
Generation of parenchymal and vessel enriched fractions  
At either 1 month (n = 10 sham/9 hypoperfused) or 3 months (n = 6/sham/ 6 hypoperfused 
group) after surgery, mice were transcardially perfused under 5% isoflurane anaesthesia with 
20 ml 0.9% heparinized PBS (pH 7.4). The brains were removed and cut along the midline. 
The left hemibrain was homogenized with a fit dounce homogenizer with 1 ml of PBS on ice, 
using 15 strokes. The homogenate was centrifuged at 250 x g for 10 minutes at 4⁰C. The 
pellet was re-suspended in 3 ml of 17.5% ficoll (Sigma) and centrifuged at 3,200 x g for 25 
minutes. The pellet (containing the vessel enriched fraction) was collected and the 
supernatant (containing the parenchymal fraction) was centrifuged again at 3,200 x g for 25 
minutes. The pellets from both spins were re-suspended in 1 ml of 1% BSA-PBS and 
centrifuged at 2,000 x g for10 minutes. The pellet was washed with 1 ml of PBS and stored at 
-80⁰C. The supernatant containing the parenchymal fraction was mixed with 6 ml of PBS and 
centrifuged at 3,200 x g for10 minutes. The supernatant was discarded and the pellet stored at 
-80⁰C. 
 
Protein extraction and quantification 
Sequential protein extraction was performed in order to obtain both soluble and insoluble 
protein fractions. Briefly, the tissue was homogenized with homogenization buffer (20 mM 
tris base pH 7.4, 250 mM sucrose, 1 mM EDTA, 1 mM EGTA, 1X protease inhibitor cocktail 
[Calbiochem]) and centrifuged at 100,000 x g for 1 hour at 4⁰C. The supernatant (containing 
the soluble protein fraction) was carefully transferred to a new tube and stored at -80⁰C. The 
pellet was resuspended and homogenized in guanidine buffer (5 M guanidine, 50 mM 
Tris/HCL) and mixed for 3 hours at room temperature (RT). The solution was diluted 1:10 
with ice-cold reaction buffer (0.2 g/L KCL, 0.2 g/L KH2PO4, 8 g/L NaCl, 1.15 g/L 
Na2HPO4, 5% BSA, 0.03% Tween 20, 1X protease inhibitor cocktail) and centrifuged at 
16,000 x g for 20 minutes at 4⁰C. The supernatant (containing the insoluble protein fraction) 
was stored at -80⁰C. Total protein extraction was performed by re-suspending the tissue in 
RIPA buffer (50 mM Tris, pH 7.5, 1% NP-40, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 
0.5% sodium deoxycholate, 1X protease inhibitor cocktail), followed by sonication for 5 
seconds at 10% amplitude (Branson digital sonifier) Samples were centrifuged at 5000 x g. 
for 5 minutes and the supernatant was collected and stored at -80⁰C. Protein levels were 
quantified with Pierce BCA Protein Assay Kit (Thermo Scientific).    
 
 
 
Enzyme-linked immunosorbent assay (ELISA) 
Levels of both Aβ1-40 and Aβ1-42 were determined by ELISA (Invitrogen) in the soluble 
and insoluble protein fractions extracted from the parenchymal and the vessel enriched 
fractions. NOX2 levels were assessed by ELISA (Cusabio) in total proteins extracted from 
brain homogenates. In all experiments, manufacturer’s instructions were used to perform the 
assays. 
 
 
Western blot 
Total proteins extracted from brain homogenates were used to detect full-length APP and 
APP-carboxyl terminal fragments (CTF’s). Proteins were fractionated by electrophoresis 
using 4–12% sodium dodecyl sulphate polyacrylamide gels (Invitrogen), electroblotted into 
PVDF membranes (Hybond-P, GE Healthcare) and incubated with the different antibodies 
(anti-APP, MAB348, anti-APP-CTF, Calbiochem 171610,). The immunoreactive bands were 
visualized using the Odyssey Infrared Imaging System (LiCor Biosciences, Lincoln, NE, 
USA). 
 
Statistical analysis  
The % parenchymal and vascular Aβ measurements (confocal imaging) were analysed for 
statistical significance between groups using Mann-Whitney U statistic with p < 0.05. ELISA 
and western blot analyses were analysed for statistical significance between groups using 
unpaired t-test with p < 0.05. For NOX2 ELISA and microinfarct studies, statistical 
comparison was carried out using two-way analysis of variance (with genotype and surgery 
as the factors) and, if data were significant (p<0.05), followed by the Bonferroni post-test. 
The number of haemorrhages were analysed for statistical significance between groups using 
Fishers exact test. For association analyses, Pearson correlation coefficient was used. All 
analyses were performed using Graph Pad Prism 5.0 software (La Jolla, CA, USA). 
 
 
 
Results 
 
Soluble Aβ levels are increased in response to cerebral hypoperfusion and precede 
insoluble Aβ accumulation in the parenchyma 
 
Initial experiments were undertaken to examine the effect of cerebral hypoperfusion on the 
levels and pools (soluble and insoluble) of Aβ. These experiments were undertaken in Tg-
SwDI mice and not wild-type mice. Aβ  is quite different in wild-type rodents as compared to 
transgenic mice with human APP mutations. In particular wild-type rodents do not naturally 
accumulate fibrillar Aβ with age most likely due to differences in the amino acid structure of 
Aβ [38]. Tg-SwDI mice develop Aβ deposits with increasing age and thus Aβ dynamics can 
be readily studied in this line [37]. In this study Tg-SwDI mice were analysed at an age when 
parenchymal Aβ deposition (and vascular) is moderate and predominantly diffuse in nature to 
assess the vulnerability to disease progression in the presence of hypoperfusion. There was no 
discernable effect of cerebral hypoperfusion on the cellular localization of Aβ (Fig. 1). 
Quantification of the parenchymal load of the protein (% parenchymal A) indicated that this 
was not significantly different between sham and hypoperfused Tg-SwDI mice after either 1 
or 3 months (p>0.05). To further investigate whether chronic hypoperfusion may have an 
effect on the different pools of Aβ within the parenchyma, the levels of soluble and insoluble 
Aβ were quantified by ELISA. After 1 month of hypoperfusion, significantly increased levels 
of both Aβ40 (p=0.02) and Aβ42 (p=0.02) were found in the soluble protein fraction, when 
compared to the sham control. In contrast, the insoluble protein fraction remained unchanged 
(p>0.05). After 3 months of hypoperfusion, there were no significant changes between the 
sham and hypoperfused groups in the soluble fraction (p>0.05), however increased 
concentrations of both Aβ40 (p=0.002) and Aβ42 (p=0.008) were observed in the insoluble 
fraction (Fig. 2). These data suggest that hypoperfusion can modify Aβ metabolism, 
triggering an early increase of soluble Aβ protein followed by aggregation into insoluble 
fibrils in the parenchyma. 
 
Delayed accumulation of vascular Aβ in response to cerebral hypoperfusion 
 
Tg-SwDI mice have a well characterized vascular accumulation of Aβ starting from 3 months 
of age particularly in the thalamus. To determine if cerebral hypoperfusion may exacerbate 
vascular accumulation of Aβ in these mice, confocal microscopy was used to quantify Aβ 
colocalization within the vasculature. After 1 month of hypoperfusion there were no changes 
in the levels of Aβ colocalized to vessels between sham and hypoperfused mice (p > 0.05, 
Fig. 3a). Conversely, following 3 months of hypoperfusion, the levels of Aβ colocalized to 
vessels significantly increased in the hypoperfused animals (p=0.04), compared to the sham 
group (Fig. 3b-d, see arrows). To further examine the pools of Aβ, the levels of Aβ40/42 
were measured in protein extracts from vessel enriched fractions (Fig. 4). There were no 
significant changes in the levels of soluble/insoluble Aβ40/42 determined between 
hypoperfused and sham animals after 1 month of hypoperfusion (p>0.05). However, 
following 3 months there was a significant increase in the levels of both Aβ40 (p=0.002) and 
Aβ42 (p=0.008) in the insoluble fraction of the hypoperfused group when compared to the 
shams and notably soluble levels of Aβ40/42 were unchanged (p>0.05). Collectively, these 
results indicate that hypoperfusion promotes the build-up of fibrillar Aβ in the 
cerebrovasculature, a process that is preceded by an increase in soluble Aβ.   
 
 
Chronic cerebral hypoperfusion increases APP levels and processing 
 
To investigate the mechanisms by which cerebral hypoperfusion may lead to increased Aβ 
levels we next sought to determine whether this process was mediated by increased amyloid 
precursor protein (APP) production or processing. Western blot analysis of brain protein 
extracts was performed using specific antibodies that recognise full-length APP and its C-
terminal fragments (CTF’s), produced after proteolytic cleavage of APP by the specific 
enzymes;  -secretase that generates CTFβ and α-secretase that results in the formation of 
CTFα (Fig. 5). Interestingly, the immunoblotting analysis revealed a significant increase in 
the levels of APP (p=0.0008), CTFβ (p=0.0002) and CTFα (p<0.0001) in the hypoperfused 
animals following 1 month, when compared to the sham group,  (Fig. 5a, c-e); however, after 
3 months of hypoperfusion no difference was observed between the two groups (p>0.05, Fig. 
5b, f-h), suggesting that the increased Aβ levels observed, might be the result of enhanced 
APP synthesis and processing, triggered at early stages during chronic cerebral 
hypoperfusion. 
 
Microinfarcts and microhemorrhages are precipitated by chronic cerebral 
hypoperfusion and Aβ 
 
The effect of chronic cerebral hypoperfusion and potential interaction with amyloid on the 
development of microinfarcts was examined in wild-type and Tg-SwDI mice following 1 and 
3 months hypoperfusion compared to shams (Fig. 6). Microinfarcts were identified in H&E 
sections as areas of tissue pallor and in adjacent sections stained with Iba1 to identify 
microglial proliferation (Fig. 6a-d). There was no evidence of microinfarcts in sham wild-
type mice but small areas of infarcted tissue were observed in sham Tg-SwDI animals (Fig. 
6e,f). After cerebral hypoperfusion there was a marked increase in microinfarcts that was 
exacerbated in Tg-SwDI mice. At one month there was a significant effect of genotype (F 
(1,38) = 14.52, p = 0.0005) and an increase in infarct area in TgSwDI mice was determined. 
The area of infarct was significantly greater in hypoperfused TgSwDI mice compared to 
sham TgSwDI mice (p < 0.05). At three months following hypoperfusion there was a 
significant effect of surgery (F (1,34) = 10.1, p = 0.003) and genotype (F (1,34) = 21.8, p < 
0.0001), and furthermore there was a significant interaction (F (1,34) = 5.45, p = 0.03) between 
surgery and genotype with a greater volume of infarct in hypoperfused TgSwDI mice (p < 
0.01). Together, this data indicates that chronic cerebral hypoperfusion increases microinfarct 
burden and that this is exacerbated in Tg-SwDI mice. 
 
There was no evidence of haemorrhages in any sham wild-type or TgSwDI mice and 
following 1 month of hypoperfusion in wild-type or TgSwDI mice. However after 3 months 
of hypoperfusion, haemorrhages were evident in one wild-type mouse and three Tg-SwDI 
mice in subcortical thalamic regions albeit this was not statistically significant 
(Supplementary Fig. S1). 
 
Aβ increases NOX2 levels, which is exacerbated by chronic cerebral hypoperfusion 
 
In order to examine the effect of both Aβ and chronic cerebral hypoperfusion on oxidative 
stress, quantitative ELISA measurement of brain protein extracts were assayed to determine 
the levels of NADPH oxidase 2 (NOX2), the main reactive oxygen species (ROS) generator 
in the brain (Fig. 7). At one month, there was a significant effect of surgery (F (1,29) = 4.29, p 
= 0.047) and significant effect of genotype (F (1,29) = 16.8, p = 0.0003) on NOX2 levels but 
there was no significant interaction. Follow up post-hoc analysis indicated that NOX2 levels 
were significantly increased in Tg-SwDI hypoperfused mice compared to Tg-SwDI shams 
(p<0.05) but there was no difference between wild-type sham and hypoperfused mice (Fig. 
7a). At 3 months, there was no significant effect of surgery (p<0.05) but there was a 
significant effect of genotype (F (1,23) = 4.7, p = 0.04) (Fig. 7b) with no significant interaction 
(p > 0.05). Thus NOX2 levels were elevated in Tg-SwDI mice. Interestingly, the increased 
levels of NOX2 positively correlated with the levels of soluble parenchymal Aβ (r = 0.66, p = 
0.002) (Fig. 7c) but no correlation was observed with levels of cerebrovascular Aβ (r = 0.085, 
p = 0.73) (Fig. 7d).  
 
 
Discussion 
 
Considerable evidence indicates that cerebral hypoperfusion, an early feature of AD brains, is 
implicated in degenerative processes and cognitive decline [1-5]. The present study sought to 
probe potential mechanistic links and investigated the effects of chronic cerebral 
hypoperfusion on Aβ dynamics in the brain of Tg-SwDI mice and its relationship with the 
development of microinfarcts. We demonstrated that mild cerebral hypoperfusion modifies 
Aβ metabolism, triggering an early increase in the levels of soluble Aβ in the parenchyma 
followed by aggregation of the protein into insoluble fibrils, with the subsequent build-up of 
aggregates in the cerebrovasculature. Furthermore, our study showed that the extent of 
microinfarcts associated with microglial proliferation was increased with hypoperfusion and 
exacerbated in the Tg-SwDI mice. Soluble parenchymal Aβ levels in Tg-SwDI mice were 
associated with elevated NOX2.  
 
Previous studies have provided conflicting evidence that modest reductions in cerebral 
perfusion can induce enhancement [20,39,40]
 
and suppression [41] of Aβ deposition. In the 
present study, we show that soluble Aβ levels are increased in response to mild cerebral 
hypoperfusion at one month  and precede insoluble Aβ accumulation in the parenchyma at 
3months. We suggest that the amount of parenchymal Aβ produced exceeds the capacity of 
normal clearance mechanisms, and thus Aβ proceeds to accumulate in the vessel walls, at the 
clearance site. Thereafter, new Aβ molecules synthesized will likely adhere to the growing 
fibrils in the parenchyma and vasculature. Our results support previous studies showing that 
cerebral amyloid angiopathy (CAA) is preceded by higher levels of soluble amyloid 
suggesting that soluble Aβ is a marker of potential CAA [42,43].  
 
Increased parenchymal Aβ levels, in response to hypoperfusion, might be the result of either 
overproduction or altered clearance of the protein, or the combination of both. Here, we show 
enhanced APP synthesis and processing, triggered at early stages during chronic cerebral 
hypoperfusion, which suggests that the increased Aβ levels observed might be the result of a 
general increase in APP metabolism, where both amyloidogenic and non-amyloidogenic 
pathways are enhanced. The latter can be concluded by the observation of increased levels of 
both C-terminal fragments (CTFs), CTFβ and CTFα respectively. Although the physiological 
function of APP is not completely understood, there is well documented evidence of a 
neurotrophic and synaptogenic role of the full-length protein [44-46]. Moreover, there are a 
number of studies showing that ischaemic injury induces intra-axonal upregulation of APP or 
increases its processing to smaller fragments [46, 47]. Thus initially, upregulation of APP and 
increased metabolism in response to hypoperfusion might be directly linked to its 
neuroprotective role. Notably though these effects on APP were short-lived and absent at 
3months post-hypoperfusion at which time an increase in insoluble A was detected.  
 
Clearance of cerebral Ais complex and regulated by several different processes including 
transport across the blood brain barrier (BBB) [48], engulfment and degradation by 
microglia/macrophage [48] and drainage pathways [48-50]. Our work has shown that BBB 
changes are not evident until six months after hypoperfusion [10] and would suggest that this 
is not a key mechanism leading to amyloid accumulation. Further the levels of low density 
lipoprotein receptor-related protein (LRP) and receptor for advanced glycation endproducts 
(RAGE), important in trafficking A across the BBB, are not altered with hypoperfusion 
(data not shown). Increased microglia were evident in the present study but it is not yet 
known whether alterations in microglia function or phagocytosis may contribute to the 
accumulation of Aβ.  In a previous study of severe chronic cerebral hypoperfusion microglial 
dysfunction and decreased phagocytic activity was suggested to contribute to enhanced Aβ 
deposition [51].  There is growing evidence that drainage pathways also play a vital role in 
the clearance of Aβ and are impacted by CAA. Thus these potential mechanisms leading to 
Aβ accumulation should be explored in the hypoperfusion model. 
 
Cerebral microinfarcts constitute a common observation in AD brains [12,13] and, as shown 
by several studies, the load of these infarcts correlates with impaired cognitive performance 
[52-54]. In this study, we show that the development of microinfarcts associated with 
microglial proliferation, is precipitated by chronic cerebral hypoperfusion, suggesting a link 
between hypoperfusion and the development of vascular lesions. Additionally, vascular 
accumulation of Aβ, which is present in almost all cases of AD, has been linked with the 
development of microinfarcts. However, the analysis of the association between CAA and 
microinfarct load remains inconclusive, with data showing a positive correlation [17,18] or  
no correlation [55] between these measures. To further examine the link between 
microinfarct load and Aβ deposition, we performed association analyses, which surprisingly 
revealed no correlation between microinfarct load and vascular or parenchymal amyloid 
levels (data not shown). However,  notably the appearance of microinfarcts was exacerbated 
in the hypoperfused  Tg-SwDI mice compared to wild-types, suggesting an underlying 
influence of amyloid on the development of these lesions. One explanation to this result 
might be attributable to the fact that the association analyses were conducted  using the 
quantification of the amyloid immunostaining which does not distinguish between the 
different pools of Aβ. Therefore, we hypothesize that rather than insoluble aggregates, 
soluble Aβ oligomers, which constitute the most cytotoxic species of Aβ, might be involved 
on the development of microinfarcts (see Fig. 8). Differences in Aβ pools could also explain 
the inconsistencies in findings between the previous studies. Indeed, compelling evidence 
supports the oligomer hypothesis, which suggests that soluble Aβ oligomers are the main 
etiologic agent that participates in the initiation of the neurodegenerative process in AD, by 
triggering a cascade of pathogenic events involving inflammation and oxidative injury [56-
60].  
 
Previous studies have shown a significant association between oxidative stress and the 
development of microinfarcts [23-28]. Consequently, to further investigate the potential 
mechanistic basis of our current finding of increased microinfarction following chronic 
cerebral hypoperfusion, we studied the levels of NOX2. We found higher NOX2 levels in the 
Tg-SwDI mice compared to the wild-type controls, and this was exacerbated by 
hypoperfusion (at one month) in the transgenic model, suggesting an additive  effect, where 
both amyloid and hypoperfusion contribute to NOX2 upregulation. Thus, NOX2-derived 
radicals may have contributed to the development of microinfarcts. Interestingly, in 
agreement with our previous hypothesis, rather than vascular Aβ, soluble parenchymal Aβ 
correlated with increased NOX2 levels, suggesting the potential participation of these species 
in the pathoetiology of microinfarcts.  
 
The evidence from the present study points towards a mechanism by which chronic cerebral 
hypoperfusion leads to an imbalance in the dynamics of Aβ metabolism. We propose a 
mechanistic pathway for the contribution of chronic cerebral hypoperfusion to cognitive 
decline and mechanisms relevant to AD (Fig. 8). Chronic cerebral hypoperfusion may 
initially increase the generation of soluble Aβ or Aβ oligomers that promote pro-
inflammatory and oxidative stress mechanisms (such as NOX2) leading to degenerative 
changes such as microinfarcts. Over time Aβ may accumulate, particularly in the vasculature, 
exacerbating vascular dysfunction and accelerating degenerative changes and  cognitive 
decline thus promoting a vicious cycle of events.  In previous studies, cerebral hypoperfusion 
has been shown to impact spatial working memory in wild-type mice [6,10]. It would be of 
translational value to determine whether cerebral hypoperfusion in TgAPP mice exacerbates 
the cognitive impairment and to further define mechanistically the interactions between 
hypoperfusion and Aβ.  
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Figure legends: 
 
Figure 1. Parenchymal Aβ deposition following chronic cerebral hypoperfusion. There 
was no statistical difference in the % parenchymal Aβ at either 1 (a) or 3 months (b)  after 
cerebral hypoperfusion compared to sham (p > 0.05). The data are presented as mean ± 
S.E.M. Representative images from sham and 3 months hypoperfused mice are shown which 
illustrate sections of the thalamus double immunostained with collagen (red) and Aβ (green). 
(scale bar = 50 µm). 
 
Figure 2. Soluble Aβ levels are increased in response to cerebral hypoperfusion and 
precede insoluble Aβ accumulation in the parenchyma. The levels of soluble and 
insoluble Aβ40/42 were quantified in the parenchymal fraction by ELISA after 1 or three 
months sham or hypoperfusion. Graphs represent the levels of the protein normalized to total 
protein concentration. The data are presented as mean ± S.E.M.. After 1 month of 
hypoperfusion, significantly increased levels of both Aβ40 (p = 0.02) and Aβ42 (p = 0.02) 
were found in the soluble protein fraction, when compared to the sham control. In contrast, 
the insoluble protein fraction remained unchanged (p > 0.05). After 3 months of 
hypoperfusion, there were no significant changes between the sham and hypoperfused groups 
in the soluble fraction (p > 0.05), however increased concentration of both Aβ40 (p = 0.002) 
and Aβ42 (p = 0.008) was observed in the insoluble fraction.  
 
Figure 3. Chronic cerebral hypoperfusion accelerates vascular amyloid. At one month 
there was no effect of hypoperfusion on vascular A load (a) whereas at 3 months vascular 
A load was significantly increased (b).  The data are presented as mean ± S.E.M., *p < 0.05. 
Representative images from sham and 3 months hypoperfused mice are shown (scale bar = 
50 µm). Double immunostaining was performed using markers of collagen (red) and Aβ 
(green). The arrows highlight amyloid localised to the vasculature.  
 
Figure 4. Delayed accumulation of vascular Aβ in response to cerebral hypoperfusion. 
The levels of soluble and insoluble Aβ40/42 were quantified in the vessel-enriched fraction 
by ELISA after 1 or three months sham or hypoperfusion. Graphs represent the levels of the 
protein normalized to total protein concentration. The data are presented as  mean ± S.E.M.. 
(a) There were no significant changes in the levels of soluble/insoluble Aβ40/42 determined 
between hypoperfused and sham animals after 1 month of hypoperfusion (p > 0.05). (b) 
However, following 3 months there was a significant increase in the levels of both Aβ40 (p = 
0.002) and Aβ42 (p = 0.008) in the insoluble fraction of the hypoperfused group compared to 
the sham animal but  soluble levels of Aβ40/42 were unchanged (p > 0.05). 
 
 
Figure 5. Chronic cerebral hypoperfusion increases APP levels and processing. Western 
blot analysis of brain protein extracts after 1 (a, c-e) and 3 (b, f-h) months of hypoperfusion 
was performed to determine the expression levels of full-length APP, CTFβ and CTFα. 
Specific bands were quantified by densitometric analysis and expressed relative to total 
tubulin protein, represented in the graphs. The data are presented as mean ± S.E.M., p < 0.05. 
There was a significant increase in the levels of APP (p = 0.0008), CTFβ (p = 0.0002) and 
CTFα (p < 0.0001) in the hypoperfused animals following 1 month  when compared to the 
sham group (c-e); however, after 3 months of hypoperfusion no difference was observed 
between the two groups (p > 0.05, f-h) 
 
Figure 6. Microinfarcts, associated with microglial proliferation, are precipitated by 
chronic cerebral hypoperfusion. Representative images showing normal (a) and infarcted 
(b) tissue using H&E staining. Iba1 staining was used to visualise microglial proliferation (c, 
d) (scale bar = 100 µm). Histopathological analysis was performed using H&E staining in 
tissue sections from Tg-SwDI and wild-type animals following 1 (e) and 3 (f) months of 
hypoperfusion; the area covered by infarcted tissue was measured and is represented in the 
graphs. The data are presented as  mean ± S.E.M.. At one month there was a significant effect 
of genotype (***p = 0.0005). The area of infarct was significantly greater in hypoperfused 
Tg-SwDI mice compared to sham Tg-SwDI mice (*p < 0.05). At three months following 
hypoperfusion there was a significant effect of surgery (**p = 0.003) and genotype (***p < 
0.0001), and furthermore there was a significant interaction (* p = 0.03) between surgery and 
genotype with a greater volume of infarct in hypoperfused Tg-SwDI mice (**p < 0.01).  
 
 
Figure 7. Aβ increases NOX2 levels, which is exacerbated by chronic cerebral 
hypoperfusion. NOX2 levels were quantified in protein extracts from brain homogenate 
using ELISA after 1 (a) and 3 (b) months of hypoperfusion. Graphs represent the levels of the 
protein normalized to total protein concentration. The data are presented as mean ± S.E.M.. 
At one month, there was a significant effect of surgery (F (1, 29) = 4.29, p = 0.047) and 
significant effect of genotype (F (1, 29) = 16.8, p = 0.0003) on NOX2 levels but there was no 
significant interaction. Follow up post-hoc analysis indicated that NOX2 levels were 
significantly increased in Tg-SwDI hypoperfused mice compared to Tg-SwDI shams (p < 
0.05) but there was no difference between wild-type sham and hypoperfused mice (p > 0.05) 
(Fig. 7a). At 3 months, there was no significant effect of surgery (p < 0.05) but there was a 
significant effect of genotype (F (1, 23) = 4.7, p = 0.04) (Fig. 7b) and no significant interaction 
(p > 0.05). There was a positive correlation between NOX2 levels and soluble parenchymal 
Aβ40 levels, r = 0.66, p = 0.002 (c) and no correlation between NOX2 levels and vascular 
Aβ40 levels, r = 0.085, p = 0.73 (d). 
 
Figure 8. Proposed mechanistic pathway for the contribution of chronic cerebral 
hypoperfusion to cognitive decline and mechanisms relevant to AD. Chronic cerebral 
hypoperfusion may initially increase the generation of soluble Aβ or Aβ oligomers that 
promote pro-inflammatory and oxidative stress mechanisms (such as NOX2) leading to 
degenerative changes such as microinfarcts. Over time Aβ may accumulate, particularly in 
the vasculature (CAA), exacerbating vascular dysfunction and accelerating degenerative 
changes and  cognitive decline thus promoting a vicious cycle of events.   
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Chronic cerebral hypoperfusion alters amyloid-β peptide pools leading to 
cerebral amyloid angiopathy, microinfarcts and haemorrhages in Tg-SwDI 
mice  
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Figure S1. Proportion of mice with thalamic hemorrhages following chronic cerebral 
hypoperfusion. Histopathological analysis was performed using Perls staining in tissue 
sections from Tg-SwDI and wild-type animals following 1 and 3 months of hypoperfusion. 
Representative images showing normal (a) and hemorrhagic (b) tissue are shown (scale bar = 
um). The number of mice with thalamic hemorrhages was determined and is indicated in the 
table.  
 
a) b)
3 months1 month
hypoperfusedsham
Wild- Type
hypoperfusedsham
0/12 (0%) 0/11 (0%) 0/10 (0%) 1/10 (10%)
Tg- SwDI 0/9 (0%) 0/10 (0%) 0/9 (0%) 3/9 (33%)
c)
